Piramal Pharma Limited (PPLPHARMA.NS)
INR 220.41
(-0.64%)
INR 220.41
(-0.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 178.2 Million INR | 109.56% |
| 2022 | -1.86 Billion INR | -149.6% |
| 2021 | 3.75 Billion INR | -34.22% |
| 2020 | 5.71 Billion INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 225.9 Million INR | 125.49% |
| 2024 Q1 | -886.4 Million INR | -187.53% |
| 2023 Q1 | -985.8 Million INR | -296.73% |
| 2023 FY | 178.2 Million INR | 109.56% |
| 2023 Q4 | 1.01 Billion INR | 901.68% |
| 2023 Q3 | 101.1 Million INR | 101.39% |
| 2023 Q2 | 50.2 Million INR | 105.09% |
| 2022 Q1 | -1.09 Billion INR | -163.72% |
| 2022 FY | -1.86 Billion INR | -149.6% |
| 2022 Q4 | 501.1 Million INR | 155.57% |
| 2022 Q3 | -901.8 Million INR | -141.51% |
| 2022 Q2 | -373.4 Million INR | 65.76% |
| 2021 Q1 | 42.65 Million INR | 0.0% |
| 2021 FY | 3.75 Billion INR | -34.22% |
| 2021 Q4 | 1.71 Billion INR | 4.76% |
| 2021 Q3 | 1.63 Billion INR | 346.85% |
| 2021 Q2 | 365.6 Million INR | 757.21% |
| 2020 FY | 5.71 Billion INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biocon Limited | 10.22 Billion INR | 98.257% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | 89.118% |
| Concord Biotech Limited | 3.08 Billion INR | 94.216% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 111.613% |
| Jubilant Ingrevia Limited | 1.82 Billion INR | 90.256% |
| Lyka Labs Limited | -24.89 Million INR | 815.835% |
| Panacea Biotec Limited | -11.73 Million INR | 1619.182% |
| SMS Lifesciences India Limited | 90.92 Million INR | -95.979% |
| Supriya Lifescience Limited | 1.19 Billion INR | 85.04% |
| Syngene International Limited | 5.1 Billion INR | 96.506% |
| TAKE Solutions Limited | -1.19 Billion INR | 114.897% |
| Zota Health Care Limited | -143.47 Million INR | 224.199% |